Numis disclosed Hvivo Plc (LON:HVO), supporting its price target at 210.00GBX earlier today
- Updated: September 22, 2016
Stating as potential upside of 0.18%, Numis hold steady the target price of Hvivo Plc (LON:HVO) at 210.00GBX
Previously on 9/22/2016, Numis reported on Hvivo Plc (LON:HVO) increased the target price from 0.00GBX to 210.00GBX. At the time, this indicated a possible upside of 0.18%.
Yesterday Hvivo Plc (LON:HVO) traded -1.64% lower at 177.50GBX. The company’s 50-day moving average is 180.66GBX and its 200-day moving average is 186.26GBX. The last closing price is down -6.27% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time period. 5,864 shares of the stock traded hands, down from an average trading volume of 29,315
See Chart Below
Hvivo Plc has a 52 week low of 167.00GBX and a 52 week high of 306.50GBX The company’s market cap is currently 0 GBX.
General Information About Hvivo Plc (LON:HVO)
hVIVO plc, formerly Retroscreen Virology Group plc, is a holding company. The Company is engaged in a life sciences business pioneering a technology platform of human disease models to accelerate drug discovery and development in respiratory and infectious diseases, including flu, respiratory syncytial virus (RSV), asthma and common cold. It has commercialized approximately four disease models, enrolled over 2,000 subjects and conducted approximately 40 product validation studies for a range of industry, government and academic clients and collaborators. The Company offers services, such as challenge study services, lab services, and target and biomarker discovery. It offers viral challenge studies in healthy volunteers in influenza, human rhinovirus (HRV) and RSV. Its lab services include assay development, transfer and optimization across the immunological, molecular and cell-based assay platforms, including offering options in sample matrix testing and specialty biomarker assays.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.